Main menu

Manchester, UK, 22 October 2008 – F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced that abstracts related to their novel antifungal agent have been selected for oral and poster presentations at the upcoming 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Walter E. Washington Conference Centre, Washington DC, 25th – 28th October 2008.

F2G will present six posters in ‘Poster session 105: New Antifungal Agents’ and the Company’s CSO, Dr Lloyd Payne, has also been allocated a speaking slot during the Saturday morning Poster Summary Session 3 entitled ‘All New Antimicrobial Agents’. Shane Kelly, Chief Executive of F2G, commented “We are delighted that the ICAAC Organising Committee has accepted our poster presentations and invited us to speak at the conference. This invitation represents an important validation of our science and is a significant achievement for the company. 2008 has been a milestone year as our candidate drug, which originates from F2G’s in-house screening program, has entered full preclinical development.”

F2G’s candidate drug represents the first generation of a novel class of systemic antifungal agent and offers the potential for a major advance in antifungal therapy. The mechanism of action, identified by scientists at F2G, involves the selective inhibition of a fungal enzyme and is completely distinct from any other class of marketed antifungal agent. The compound displays highly potent activity against a wide range of clinically significant moulds including the common pathogen Aspergillus fumigatus which is known to cause Invasive Aspergillosis, a serious, debilitating disease associated with high mortality rates despite current therapy options.

The planned poster presentations at ICAAC 2008 highlight the potent in vitro antifungal activity of the new compound against a wide range of clinically significant fungi including Aspergilli sp. The pharmacokinetics profile of the agent and its ADMET properties are described as well as data pertaining to the excellent efficacy of the novel agent in highly validated models of Aspergillus infection.

About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over five and a half billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.

F2G recently completed a £6.3million equity financing round with an international syndicate of investors to fund the further development of the company’s lead compound and back-up programs. The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs.

For more information visit www.f2g.com

Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Manchester, UK, 18th August 2008 – F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the completion of a £6.3 million equity financing round with an international syndicate of investors.

The funding will be used, in part, to support the development of F2G’s novel antifungal lead compound which is currently in pre-clinical development. FG3622 is a potent, novel, small molecule antifungal, active against a wide range of clinically significant moulds. In addition it has a new Mechanism of Action for systemic antifungal agents.

F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over five and a half billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.

The funding, led by BankInvest Biomedical Venture (Denmark), will allow F2G to accelerate the development of FG3622 and other novel antifungal agents. Merifin Capital, Astellas Venture Management and K Nominees also participated in the financing round.

Mr Shane Kelly, CEO of F2G Ltd, said: “This financing is a strong endorsement of the outstanding work performed by the F2G team. We are delighted with the continued support from our investors and the current funding represents complete validation of our lead program and other ongoing projects. The resources will allow the Company to push through the development of FG3622 and other interesting programs.”

Mr Jens Kindtler, Partner at BankInvest Biomedical Venture and Chairman of the F2G Board of Directors, commented: “We are delighted to continue our support of F2G. FG3622 is an exciting, novel molecule that will impact heavily on the current antifungal market. There is significant clinical need for a new systemic agent and FG3622 has the potential to fulfil this gap.”

For more information visit www.f2g.com

Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Manchester, England, 10th January 2007 – F2G Limited, specialists in research and development of new treatments for serious fungal infections in man, is pleased to announce the appointment of Dr Lloyd Payne as Chief Scientific Officer.

This appointment signifies a promotion for Dr Payne who joined F2G Ltd as Vice President of Research and Development in April 2006. He had previously held senior scientific and management positions within Cambridge Discovery Chemistry Ltd, NCE Discovery Ltd and more recently at Millennium Pharmaceuticals where he was responsible for the leadership of multidisciplinary drug discovery project teams based in the UK and US.

Dr Payne takes over the CSO position from Dr Jeff Edwards who is assuming the Chairmanship of the Board Science Committee.

Shane Kelly, Chief Executive of F2G, stated “We have been very impressed with the positive impact Lloyd has had on our scientific progress since he joined the Company. I personally wish Lloyd and Jeff every success in their new roles and thank them for their efforts to date”.

Lloyd Payne commented “F2G is focused on the development of novel therapies for the treatment of life-threatening fungal infections and has assembled an impressive range of capabilities in fungal biology and drug discovery. This is an exciting stage of the Company’s evolution and I look forward to working with the team to enable continued progression of current programs towards the market.”

F2G’s technologies focus on the development of new and innovative drug treatments for systemic fungal infections in man. This market is currently estimated at over five and a half billion dollars annually and is growing at approximately 20% per year. In addition, there is new evidence suggesting a correlation between fungal infections and allergic conditions (including asthma). If proven, this would add significantly to the growth of the total addressable market. F2G has developed unique capabilities in the field including proprietary genomic targets, target validation, drug discovery and drug development. The Company has also amassed unique expertise in the fields of clinical need and corporate and business development specific to the field.

For more information visit www.f2g.com

Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Manchester, England, 26th September 2006 – F2G Limited, specialists in research and development of new treatments for serious fungal infections in man, is pleased to announce the appointment of Dr Richard J. White to the Board of Directors.

Dr White has a wealth of experience in infectious disease drug discovery. Following a post-doctoral fellowship on microbial biochemistry at Oxford University, England, he spent the first 28 years of his career in the pharmaceutical industry in positions at Lepetit (Italy), Glaxo (UK), Lederle (USA), and at Bristol Myers Squibb in Connecticut, where he was Vice President in charge of Infectious Disease Drug Discovery for 12 years. There he was involved with the Discovery/Development of the cephalopsporins Cefepime and Cefprozil, and the AIDS drugs Didanosine and Zerit. In 1997 he moved to Biotech taking a position at Versicor in California where he became Chief Scientific Officer. In the ensuing 8 years he played an important role in licensing in and development of Dalbavancin and Anidulafungin, taking Versicor public, merging with Biosearch Italia to create Vicuron, and ultimately in achieving a market capital of 1.9 billion dollars when it was sold to Pfizer in September 2005.

Shane Kelly, Chief Executive of F2G commented “Dr White’s involvement will be extremely beneficial as our programs enter the clinic. His strong experience with Biotech and Pharma brings a great balance to the Board of F2G. He understands the needs and challenges of emerging companies, and has successfully navigated the complex waters of leading such companies to a successful position.”

Mr Jens Kindtler, Chairman of the Board added “We are delighted to welcome Richard White to the Board. His vast experience in the development of anti-infective drugs within biotech and large pharma, combined with his commercial acumen, will be a valuable addition to the Board. I look forward to working with him towards the further development of F2G.”

Richard J. White said “F2G is an exciting company focused on a unique niche in an expanding market. I am very pleased to be working with the Board towards the further development of the company’s programs and the progression of new antifungal drugs through the clinic to market.”

F2G’s technologies focus on the development of new and innovative drug treatments for systemic fungal infections in man. This market is currently estimated at over five and a half billion dollars annually and is growing at approximately 20% per year. In addition, there is new evidence suggesting a correlation between fungal infections and allergic conditions (including asthma). If proven, this would add significantly to the growth of the total addressable market.

F2G has developed unique capabilities in the field including proprietary genomic targets, target validation, drug discovery and drug development. They have also amassed unique expertise in the fields of clinical need and corporate and business development specific to the field.

F2G’s lead investors are BankInvest Biomedical Venture, a leading life science investor dedicated primarily to the drug development segment, and Merifin Capital, a European private investment group. Astellas Venture Management LLC, the corporate venture capital arm of Astellas Pharma Inc, joined the syndicate of existing investors in March 2006.

For more information visit www.f2g.com

Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Manchester, England, 18th April 2006 – F2G Limited, specialists in research and development of new treatments for serious fungal infections in man, is pleased to announce the appointment of Dr Lloyd Payne as Vice President of Research and Development.

Dr Payne was previously a senior scientist at Millennium Pharmaceuticals where he was responsible for the leadership of multidisciplinary drug discovery project teams based in the UK and the US. Lloyd provided direction for a number of medicinal chemistry programs from early hit validation to late stage lead optimisation and has led several successful projects focused on the development of therapies for inflammatory disorders and cancer. One such program has since delivered a novel, orally administered small molecule therapeutic into the clinic.

Lloyd has also held senior scientific and management positions within Cambridge Discovery Chemistry Ltd and NCE Discovery Ltd where he was responsible for a number of collaborative medicinal chemistry projects working with organisations across Europe, Japan and the U.S.

Lloyd’s experience will be invaluable as F2G’s projects move toward the clinic.
Shane Kelly, Chief Executive of F2G commented “We are delighted to welcome Lloyd to our world-class team. He has the technical and leadership skills that will accelerate the development of our programs and bring new anti fungal drugs through the clinic and onto the market. He is an outstanding addition to our scientific team.”

F2G’s technologies focus on the development of new and innovative drug treatments for systemic fungal infections in man. This market is currently estimated at over five and a half billion dollars annually and is growing at approximately 20% per year. In addition, there is new evidence suggesting a correlation between fungal infections and allergic conditions (including asthma). If proven, this would add significantly to the growth of the total addressable market.

F2G has developed unique capabilities in the field including proprietary genomic targets, target validation, drug discovery and drug development. They have also amassed unique expertise in the fields of clinical need and corporate and business development specific to the field.

For more information visit www.f2g.com

Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd

Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com

Find us

Contact us

F2G Ltd
Lankro Way
Eccles
Manchester
United Kingdom
M30 0LX

Telephone | +44 (0)161 785 1270
Fax | +44 (0)161 785 1273
email |  contact@f2g.com


Registered in England and Wales. Company Registration No. 03578625, VAT Reg No. 712680645.